Cilostazol in a Child With Moyamoya Disease

Moyamoya disease is characterized by progressive stenosis of the terminal internal carotid arteries and their branches with secondary angiogenesis of lenticulostriate collateral vessels. Although surgical revascularization decreases the risk of ischemic and hemorrhagic strokes, there remains little evidence demonstrating safety and efficacy of nonsurgical interventions in pediatric moyamoya. Recent data support the use of cilostazol in adult moyamoya, but cilostazol safety and efficacy in pediatric moyamoya remains unknown. We report the case of a 9-year-old girl diagnosed with MMD following a large right MCA stroke who experienced frequent transient neurologic events consisting of dysarthria and left-sided drooling after pial synangiosis. After unsuccessful trials of antiseizure medications and blood pressure augmentation, the events ultimately abated after the addition of cilostazol. Episodes recurred but again subsided after cilostazol dosing adjustment. This case suggests that cilostazol may be safe and effective for management of pediatric MMD and highlights the need for further investigation.

Authors

Institutions

Publication Details

Journal
Journal of Child Neurology
Published
2026-01-08
DOI
https://doi.org/10.1177/08830738251408110
Citations
1
Primary Topic
Moyamoya disease diagnosis and treatment
Type
article
Field-Weighted Citation Impact
46.80
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Cilostazol in a Child With Moyamoya Disease

A. Scott Patterson, April Sharp, Risheng Xu, Sarah K. D. Vogel et al.
1 citations
Journal of Child Neurology
Moyamoya disease diagnosis and treatment
46.80
article

Cilostazol in a Child With Moyamoya Disease

A. Scott Patterson, April Sharp, Risheng Xu, Sarah K. D. Vogel, Alan Cohen, Lisa R. Sun
article en
1 citations

Abstract

Moyamoya disease is characterized by progressive stenosis of the terminal internal carotid arteries and their branches with secondary angiogenesis of lenticulostriate collateral vessels. Although surgical revascularization decreases the risk of ischemic and hemorrhagic strokes, there remains little evidence demonstrating safety and efficacy of nonsurgical interventions in pediatric moyamoya. Recent data support the use of cilostazol in adult moyamoya, but cilostazol safety and efficacy in pediatric moyamoya remains unknown. We report the case of a 9-year-old girl diagnosed with MMD following a large right MCA stroke who experienced frequent transient neurologic events consisting of dysarthria and left-sided drooling after pial synangiosis. After unsuccessful trials of antiseizure medications and blood pressure augmentation, the events ultimately abated after the addition of cilostazol. Episodes recurred but again subsided after cilostazol dosing adjustment. This case suggests that cilostazol may be safe and effective for management of pediatric MMD and highlights the need for further investigation.

Journal of Child Neurology
Kennedy Krieger Institute (US), Johns Hopkins University (US), Johns Hopkins Medicine (US)
Good health and well-being
Openalex Percentile: Top 2%
Moyamoya disease diagnosis and treatment
46.80
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Cilostazol in a Child With Moyamoya Disease — A. Scott Patterson, April Sharp, et al. · Journal of Child Neurology (2026) | TGRS Research Map | TGRS